Synthesis of regioselectively acylated quercetin analogues with improved antiplatelet activity

Duan,Yu; Sun,Na; Xue,Min; Wang,Xiaolan; Yang,Hu

doi:10.3892/mmr.2017.7781

Synthesis of regioselectively acylated quercetin analogues with improved antiplatelet activity

Authors:
- Yu Duan
- Na Sun
- Min Xue
- Xiaolan Wang
- Hu Yang
View Affiliations

Affiliations: School of Pharmacy, Weifang Medical College, Weifang, Shandong 261053, P.R. China, Department of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, VA 23119, USA
Published online on: October 12, 2017 https://doi.org/10.3892/mmr.2017.7781
Pages: 9735-9740

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to report on a complete synthetic approach, namely benzylation-hydrolysis-acylation‑hydrogenation, to the synthesis of regioselectively acylated quercetin analogues using low‑cost rutin as a starting material. Three quercetin analogues, quercetin‑3‑O‑propionate (Q‑pr), quercetin‑3‑O‑butyrate (Q‑bu) and quercetin‑3‑O‑valerate (Q‑va), containing 3‑, 4‑ and 5‑carbon aliphatic acyl chains, respectively, were synthesized and characterized with 1H nuclear magnetic resonance (NMR), 13C NMR and mass spectrometry. Compared with quercetin, all three analogues exhibited improved lipophilicity. The lipophilicity of the analogue increased with increasing acyl chain length. Q‑va exhibited the highest lipophilicity among the three analogues, but a lower water solubility compared with quercetin. By contrast, Q‑pr and Q‑bu exhibited 8.2‑ and 4.7‑fold higher water solubility compared with quercetin, respectively. The in vitro and in vivo studies demonstrated that Q‑pr and Q‑bu were more effective whereas Q‑va was less effective in inhibiting platelet aggregation compared with quercetin. These results indicated that the water solubility and the lipophilicity of the analogues must be improved in order to achieve higher antiplatelet activity, and an optimal acyl chain length is crucial for the synthesized quercetin analogues to be more effective.

View Figures

View References

1	Hertog MG, Hollman PC, Katan MB and Kromhout D: Intake of potentially anticarcinogenic flavonoids and their determinants in adults in the Netherlands. Nutr Cancer. 20:21–29. 1993. View Article : Google Scholar : PubMed/NCBI
2	Chen Y and Deuster P: Comparison of quercetin and dihydroquercetin: Antioxidant-independent actions on erythrocyte and platelet membrane. Chem Biol Interact. 182:7–12. 2009. View Article : Google Scholar : PubMed/NCBI
3	Fuentes E and Palomo I: Relationship between Platelet PPARs, cAMP levels, and P-Selectin expression: Antiplatelet activity of natural products. Evid Based Complement Alternat Med. 2013:8617862013. View Article : Google Scholar : PubMed/NCBI
4	Fuentes E and Palomo I: Antiplatelet effects of natural bioactive compounds by multiple targets: Food and drug interactions. J Funct Foods. 6:73–81. 2014. View Article : Google Scholar
5	Mosawy S, Jackson DE, Woodman OL and Linden MD: Treatment with quercetin and 3′,4′-dihydroxyflavonol inhibits platelet function and reduces thrombus formation in vivo. J Thromb Thrombolys. 36:50–57. 2013. View Article : Google Scholar
6	Navarro-Núñez L, Lozano ML, Martínez C, Vicente V and Rivera J: Effect of quercetin on platelet spreading on collagen and fibrinogen and on multiple platelet kinases. Fitoterapia. 81:75–80. 2010. View Article : Google Scholar : PubMed/NCBI
7	Navarro-Núñez L, Rivera J, Guerrero JA, Martínez C, Vicente V and Lozano ML: Differential effects of quercetin, apigenin and genistein on signalling pathways of protease-activated receptors PAR(1) and PAR(4) in platelets. Brit J Pharmacol. 158:1548–1556. 2009. View Article : Google Scholar
8	Oh WJ, Endale M, Park SC, Cho JY and Rhee MH: Dual roles of quercetin in platelets: Phosphoinositide-3-kinase and MAP kinases inhibition, and cAMP-dependent vasodilator-stimulated phosphoprotein stimulation. Evid Based Complement Alternat Med. 2012:4852622012. View Article : Google Scholar : PubMed/NCBI
9	Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J and Kerr DJ: Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 2:659–668. 1996.PubMed/NCBI
10	Leonarduzzi G, Testa G, Sottero B, Gamba P and Poli G: Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids. Curr Med Chem. 17:74–95. 2010. View Article : Google Scholar : PubMed/NCBI
11	Justino GC, Santos MR, Canário S, Borges C, Florêncio MH and Mira L: Plasma quercetin metabolites: Structure-antioxidant activity relationships. Arch Biochem Biophys. 432:109–121. 2004. View Article : Google Scholar : PubMed/NCBI
12	Wang H and Joseph JA: Structure-activity relationships of quercetin in antagonizing hydrogen peroxide-induced calcium dysregulation in PC12 cells. Free Radic Biol Med. 27:683–694. 1999. View Article : Google Scholar : PubMed/NCBI
13	Montenegro L, Carbone C, Maniscalco C, Lambusta D, Nicolosi G, Ventura CA and Puglisi G: In vitro evaluation of quercetin-3-O-acyl esters as topical prodrugs. Int J Pharm. 336:257–262. 2007. View Article : Google Scholar : PubMed/NCBI
14	Saija A, Tomaino A, Trombetta D, Pellegrino ML, Tita B, Messina C, Bonina FP, Rocco C, Nicolosi G and Castelli F: ‘In vitro’ antioxidant and photoprotective properties and interaction with model membranes of three new quercetin esters. Eur J Pharm Biopharm. 56:167–174. 2003. View Article : Google Scholar : PubMed/NCBI
15	Gatto MT, Falcocchio S, Grippa E, Mazzanti G, Battinelli L, Nicolosi G, Lambusta D and Saso L: Antimicrobial and anti-lipase activity of quercetin and its C2-C163-O-acyl-esters. Bioorg Med Chem. 10:269–272. 2002. View Article : Google Scholar : PubMed/NCBI
16	Kumar V, Jahan F, Mahajan RV and Saxena RK: Efficient regioselective acylation of quercetin using Rhizopus oryzae lipase and its potential as antioxidant. Bioresour Technol. 218:1246–1248. 2016. View Article : Google Scholar : PubMed/NCBI
17	Sardone L, Pignataro B, Castelli F, Sarpietro MG, Nicolosi G and Marletta G: Temperature and pressure dependence of quercetin-3-O-palmitate interaction with a model phospholipid membrane: Film balance and scanning probe microscopy study. J Colloid Interface Sci. 271:329–335. 2004. View Article : Google Scholar : PubMed/NCBI
18	Yamauchi K, Mitsunaga T, Inagaki M and Suzuki T: Synthesized quercetin derivatives stimulate melanogenesis in B16 melanoma cells by influencing the expression of melanin biosynthesis proteins MITF and p38 MAPK. Bioorg Med Chem. 22:3331–3340. 2014. View Article : Google Scholar : PubMed/NCBI
19	Wuts PGM and Greene TW: Protection for Phenols and CatecholsGreene's Protective Groups in Organic Synthesis. John Wiley & Sons; New York: pp. 367–430. 2006, View Article : Google Scholar
20	Bonina FP, Montenegro L, De Capraris P, Bousquet E and Tirendi S: 1-Alkylazacycloalkan-2-one esters as prodrugs of indomethacin for improved delivery through human skin. Int J Pharm. 77:21–29. 1991. View Article : Google Scholar
21	Braumann T: Determination of hydrophobic parameters by reversed-phase liquid chromatography: Theory, experimental-techniques, and application in studies on quantitative structure-activity-relationships. J Chromatogr. 373:191–225. 1986. View Article : Google Scholar : PubMed/NCBI
22	Mosawy S, Jackson DE, Woodman OL and Linden MD: Treatment with quercetin and 3′,4′-dihydroxyflavonol inhibits platelet function and reduces thrombus formation in vivo. J Thromb Thrombolys. 36:50–57. 2013. View Article : Google Scholar